School of Medicine
Showing 41-60 of 163 Results
-
Jennifer Chie Schymick
Clinical Assistant Professor (Affiliated), Pediatrics - Genetics
BioPROFESSIONAL EDUCATION
∗ Medical Genetics Fellowship Stanford University (2018-2020)
∗ General Internal Medicine Residency University of Toronto (2013-2018)
∗ M.D. University of California Irvine (2009-2013)
∗ Ph.D. Oxford University & National Institutes of Health (2005-2009)
∗ B.Sc. Massachusetts Institute of Technology (1998-2002) -
Christopher Thomas Scott, PhD
Sr Research Scholar, Pediatrics - Center for Biomedical Ethics
Current Research and Scholarly InterestsMy research focuses on the political, legal, ethical and economic impacts of stem cell research. Topics include: embryonic and adult stem cell research and clinical trials, stem cell banking, human-animal chimeras; cell and gamete donation; international perspectives of bioethics; global economic impacts; national and state regulatory policy, stem cell entrepreneurship, intellectual property and offshore stem cell transplants.
-
Talal Seddik
Clinical Associate Professor, Pediatrics - Infectious Diseases
Current Research and Scholarly InterestsTalal Seddik is a member of the Collaborative Antiviral Study Group. He is the key site investigator at the Stanford site for the following multicenter studies:
1) DMID 19-0026 Enterovirus Study
Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality
This study will be the first large, multi-state prospective assessment of the viral causes of neonatal sepsis conducted. The main reason for this research study is to get a better understanding of what causes neonatal viral sepsis and to assess the impact of the infection on the babies’ health. Viruses called enterovirus (EV) or human parechovirus (HPeV) are very common in the population and can cause neonatal viral sepsis. By gaining a better understanding of the condition, we hope this information can be used to guide diagnosis and treatment of babies with neonatal viral sepsis in the future.
This study is actively enrolling subjects
2) DMID 19-0005 Acute Flaccid Myelitis (AFM) Study
A Prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors and Pathogenetic Mechanisms
Patients with suspected AFM (onset of flaccid limb weakness within the previous 30 days) are eligible to enroll in the study. Investigators will assess participants at four-time points within the first month of enrollment and will ask participants to return for additional follow up visits at 3 months, 7 months and 1 year. Neurologic improvements will be tracked over time, and samples will be collected and stored in a biorepository for use in future research studies. Household contacts, such as siblings, will be eligible to participate in the study as a control or comparison group.
This study is actively enrolling subjects. -
Zachary M. Sellers, MD, PhD
Assistant Professor of Pediatrics (Gastroenterology)
BioI am a pediatric physician-scientist striving to advance cystic fibrosis clinical care and translational research. Clinically, I am focused on gastrointestinal manifestations of cystic fibrosis, developing diagnostic and therapeutic modalities to improve the gastrointestinal and liver health of those with cystic fibrosis. I also specialize in the clinical management of pediatric pancreatitis and am involved with the international INSPPIRE consortium to study pediatric pancreatitis. My research spans the entire spectrum across basic science and translational research to clinical research and trials. In the laboratory, my projects are centered around understanding mechanisms of ion transport in cystic fibrosis tissues and determining how loss of CFTR ion transport leads to pathologic changes in human physiology. We are also very interested in the pathophysiological relationship between pancreatitis and intestinal diseases, such as inflammatory bowel disease. Our laboratory has expertise in epithelial ion transport, with specialized skills in the measurement of bicarbonate transport. We are also part of a Multi-PI collaboration pursuing CFTR gene editing and stem cell engraftment for the treatment of cystic fibrosis. We utilize a combination of immortalized and primary cell culture, organoids, mouse and human tissue, and whole animal in vivo studies.
-
Ami J. Shah
Clinical Professor, Pediatrics - Stem Cell Transplantation
BioI joined Stanford University in 2015 as a Clinical Professor of Pediatrics in the Division of Hematology/ Oncology, Stem Cell Transplantation and Regenerative Medicine, having completed my training in Pediatric Hematology/ Oncology at Childrens Hospital Los Angeles. My areas of clinical expertise have been in the areas of transplantation for immune deficiencies and immune reconstitution post HSCT. I have been actively involved with the care and treatment of children with primary immune deficiencies and work with the Primary Immune Deficiencies Consortium (PIDTC). I am very interested in cellular therapies as a treatment modality for rare genetic diseases. I currently am the PI for several gene therapy trials at Stanford for various disorders including cerebral adrenoleukodystrophy (cALD), Sickle Cell Anemia, Thalassemia and Pyruvate Kinase Deficiency. My other main areas of research have been in studying the late effects of patients following stem cell transplantation, in specific the neurocognitive function post HSCT. I have been involved with several national committees addressing the late effects of HSCT within the ASBMT and COG.
In addition to my research work in stem cell transplantation, I have been actively involved with mentorship and graduate medical education. I am currently the Program Director for the Hematology/ Oncology Fellowship and serve as a mentor through the Pediatric Mentoring Group. -
Mona D. Shah, MD, MBA
Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology
BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.
Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.
Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.
After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.
Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!
Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family. -
Sejal Shah
Clinical Assistant Professor, Pediatrics - Endocrinology and Diabetes
Current Research and Scholarly InterestsMy primary research interest is evaluating whether vitamin D supplementation can positively affect consequences of the metabolic syndrome in overweight and obese adolescents. Other research interests include evaluating the efficacy and biochemical profiles of various types of estrogen replacement in adolescent females.
-
Paul Sharek MD, MPH
Professor of Pediatrics (Hospital Medicine) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsResearch interests centered on hospital based quality of care improvement, and in particular pediatric patient safety. Areas of recent interest include developing practical tools to more accurately identify adverse medical events and to establish national rates of these adverse events. Additional areas of interest focus on developing the processes and systems to decrease the frequency of adverse drug events and adverse medical events at Children's hospitals in North America
-
Aditi Sharma
Basic Life Res Scientist, Pediatrics - General Pediatrics
Current Role at StanfordResearch Scientist
